Glenmark Pharmaceuticals is currently trading at Rs. 351.70, up by 1.85 points or 0.53% from its previous closing of Rs. 349.85 on the BSE.
The scrip opened at Rs. 351.00 and has touched a high and low of Rs. 354.40 and Rs. 348.70 respectively. So far 107338 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 706.90 on 31-Dec-2018 and a 52 week low of Rs. 267.30 on 14-Nov-2019.
Last one week high and low of the scrip stood at Rs. 359.25 and Rs. 336.40 respectively. The current market cap of the company is Rs. 9922.44 crore.
The promoters holding in the company stood at 46.58%, while Institutions and Non-Institutions held 38.80% and 14.62% respectively.
Mankind Pharmaceuticals has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country. Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm.
This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen Mankind Pharma’s diabetes portfolio but also help consolidate its position as the fastest-growing player in the anti-diabetes segment.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1545.25 |
Dr. Reddys Lab | 5861.00 |
Cipla | 1356.95 |
Zydus Lifesciences | 984.75 |
Lupin | 1635.00 |
View more.. |